Atieh Karimzadeh: Romiplostim Shows High Response and Reduced Bleeding in Pediatric HSCT
Atieh Karimzadeh, Postdoctoral Research Fellow at the Pediatric Cell and Gene Therapy Research Center, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Transplantation and Cellular Therapy, adding:
“Excited to share another publication from our team!
Our study, ‘Efficacy and Safety of Romiplostim in Treating Thrombocytopenia after Hematopoietic Stem Cell Transplantation in Pediatric Patients‘, has been published in the Transplantation and Cellular Therapy (Q1, IF=4.4)
In the largest prospective pediatric study to date on this topic, we found that romiplostim achieved an impressive 80.9% response rate, significantly reduced bleeding events, and
helped most patients become transfusion-independent – all with an excellent safety profile.
These findings highlight the potential of romiplostim as an effective supportive care strategy for children experiencing prolonged thrombocytopenia after HSCT.
Special thanks to Amir Ali Hamidieh and Maryam Behfar for their invaluable mentorship, guidance, and support throughout this project.
Shout out to the brilliant Zahra Karimizadeh for this amazing collaboration.
Proud to contribute to advancing pediatric HSCT research and improving patient outcomes.”
Title: Efficacy and Safety of Romiplostim in Treating Thrombocytopenia after Hematopoietic Stem Cell Transplantation in Pediatric Patients: A Single-Arm Clinical Trial
Authors: Zahra Karimizadeh, Maryam Behfar, Atieh Karimzadeh, Leila Jafari, Amirali Kalantari, Zeynab Nikfetrat, Amir Ali Hamidieh
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 5, 2026, 15:50Venugopalan Unni: D-Dimer and Pulmonary Embolism
-
Jun 5, 2026, 15:48Surbhi Singh: Platelet Satellitism – When Platelets Cluster Around Neutrophils and Mimic Thrombocytopenia
-
Jun 5, 2026, 15:39Wolfgang Miesbach: CMA CAR-T Induces Immune Reset and Durable Remission in Refractory ITP – EHA 2026 Late-Breaking Update
-
Jun 5, 2026, 15:34Ney Carter Borges: Low-Dose Rivaroxaban in Advanced Chronic Kidney Disease – Lessons From the TRACK Trial
-
Jun 5, 2026, 15:29Nethuki Kulasinghe: Sequential Anticoagulation in Postpartum Iliocaval Thrombosis With Submassive PE and HIT
-
Jun 5, 2026, 15:23Michelle Leona Cecil: Microhealth – Digital Health Platform for Bleeding Disorders Community
-
Jun 5, 2026, 15:23Claudia Rizk: Collaborative Endovascular Intervention Enables Successful Treatment of Acute Limb Ischemia
-
Jun 5, 2026, 15:10Amna Ahmed: A Step Closer to Solving Bleeding Disorders of Unknown Cause
-
Jun 5, 2026, 14:44Jan T. Kielstein: Bleeding Risk Outweighs Potential Benefits of Rivaroxaban in CKD Patients